The authors state that they have no significant financial or other relationship with the manufacturer of any commercial product or provider of any commercial service discussed in the material they contributed to this publication or with the manufacturer or provider of any competing product or service.

The American Academy of Ophthalmology provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, or to replace a physician's own judgment or to provide specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, using current information included in the manufacturer's package inserts or other independent sources, and considered in light of the patient's condition and history. Reference to certain drugs, instruments, and other products in this publication is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some materials may include information on applications that are not considered community standard that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate patient consent in compliance with applicable law. The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.


Slide 44 is reproduced, with permission, from Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for Diabetic Macular Edema: Early Treatment Diabetic Retinopathy Study Report Number 1. Archives of Ophthalmology. 103:1796-1806. Copyright © 1985, American Medical Association. All rights reserved.

Slide 48 is adapted, with permission, from Ferris FL, Davis MD, and Aiello LM. Drug therapy: treatment of diabetic retinopathy. New Engl J Med. 1999;341(9):667-78. Copyright © 1999, Massachusetts Medical Society. All rights reserved.
## CONTENTS

A GUIDE TO PRESENTING **DIABETES AND EYE DISEASE** ........................................... 3

INTRODUCTION .................................................................................................................. 4

SYSTEMIC CONTROLS ...................................................................................................... 5
  Glucose ..............................................................................................................................................5
  Hypertension ......................................................................................................................................7
  Additional Systemic Controls ............................................................................................................8
    Diabetic Retinopathy and Cardiovascular Disease .....................................................................9

PATHOGENESIS .................................................................................................................. 9

CLINICAL STAGES OF RETINOPATHY ............................................................................ 10
  Nonproliferative Diabetic Retinopathy .........................................................................................11
  Preproliferative Diabetic Retinopathy .........................................................................................13
  Proliferative Diabetic Retinopathy ...............................................................................................13

DIAGNOSIS ........................................................................................................................ 16

TREATMENT ...................................................................................................................... 17
  Laser Photocoagulation for Macular Edema ....................................................................................18
  Laser Photocoagulation for Proliferative Retinopathy .................................................................19
  Vitrectomy .......................................................................................................................................20
  Treatment Options: Summary ..........................................................................................................21

SCREENING GUIDELINES ................................................................................................ 22

CONCLUSION .................................................................................................................... 23

REFERENCES ................................................................................................................... 25

APPENDIX 1: RECOMMENDED EYE EXAMINATION SCHEDULE .................................. 28

APPENDIX 2: RESOURCES .............................................................................................. 29
**A GUIDE TO PRESENTING**

**Diabetes and Eye Disease**

*Diabetes and Eye Disease* is a slide-script program for primary care physicians and other medical professionals who care for patients with diabetes.

Although diabetic retinopathy, a serious vision-threatening complication of diabetes, is the leading cause of new blindness in adults aged 20-74, it is estimated that blindness can be prevented in most of these cases. For this reason, the early diagnosis and referral of patients with diabetic retinopathy is essential.

The goal of this program is to enhance primary care physicians’ awareness and knowledge of diabetic retinopathy as well as their diagnostic and management skills. The program provides information on the epidemiology, pathophysiology, diagnosis, and management of diabetic retinopathy. Specific referral guidelines are given, and a section on therapy is included to allow the health practitioner to more effectively describe laser surgery and vitrectomy to the patient. The management principles outlined in this slide-script are based in large measure on NIH-sponsored multicenter prospective trials.

**Approximate Running Time**

45-75 minutes

**Suggested Audience**

- Medical students
- Family physicians
- Internists
- Diabetologists (adult and pediatric)
- First-year ophthalmology residents
- American Association of Diabetes Educators (member organization)
- Physicians’ assistants
- Nurses and nurse practitioners
INTRODUCTION

The goal of this presentation is to strengthen the role of the primary care physician and other medical professionals in preventing vision loss from diabetic retinopathy. At the end of this presentation, the participant should be able to identify systemic risk factors of diabetic retinopathy, distinguish among the various stages of retinal disease, describe treatment strategies and screening guidelines for diabetic patients, and recognize the importance of communication between primary care physicians and ophthalmologists.

Diabetes mellitus is a ubiquitous disease of enormous proportion. Worldwide, 135 million people are affected, a number expected to increase to 300 million by 2025. Ninety percent of these patients have type 2 (non–insulin-dependent) diabetes. The disease has reached epidemic numbers in many developing nations.

Diabetes affects nearly 18 million Americans, at least one third of whom have not yet been diagnosed. Each year, 800,000 new cases of type 2 diabetes are diagnosed in the United States. Minority communities are particularly at risk. African-Americans, Latinos, and native Americans are roughly twice as likely as Caucasians to be affected.
The retinal complications of diabetes, called diabetic retinopathy, are the leading cause of blindness in working-age Americans. The American Diabetes Association reports that 12,000 to 24,000 people with diabetes lose their sight each year.

Patients who have retinopathy and who are under the care of an ophthalmologist should adhere to a follow-up examination schedule determined by the ophthalmologist in cooperation with the primary care physician. A team approach to achieving tight glycemic control, timely screening, and early treatment will maximize the patient’s ocular and systemic prognosis.

SYSTEMIC CONTROLS

Glucose

The Diabetes Control and Complications Trial (DCCT), a prospective clinical trial sponsored by the NIH, recruited 1400 patients with insulin-dependent (type 1) diabetes in the United States and Canada. Patients with no baseline retinopathy and patients with mild to moderate nonproliferative diabetic retinopathy (NPDR) were randomized between two treatment groups—conventional or intensive therapy. The DCCT demonstrated that intensive glucose control reduces the rate of development and progression of diabetic retinopathy in type 1 patients with and without baseline retinopathy.
Intensive glucose control also reduces the development and progression of diabetic retinopathy in patients with mild to moderate retinopathy at baseline.

Patients in the intensive treatment group achieved glycemic control with insulin pumps or three or more daily insulin injections and frequent home blood glucose monitoring. Those in the conventional group received no more than two daily insulin shots and less frequent glucose monitoring. Both groups were observed for an average of 6.5 years. Patients with no baseline retinopathy who used intensive therapy showed a 27% reduction in developing retinopathy and a 76% reduction in developing more progressive retinopathy.

Patients with baseline (mild to moderate NPDR) retinopathy who received intensive treatment showed a 54% reduction in the progression of retinopathy, a 47% reduction in the development of severe NPDR or proliferative diabetic retinopathy (PDR), and a 59% reduction in the need for laser surgery. It should be noted that during the early stages of intensive management, pre-existing retinopathy may worsen.
This study is an extension of the DCCT that showed that initial glycemic control has long term benefit. After completion of the DCCT the intensive and standard control groups were followed for an additional 2 to 3 years. Even though the A1C median leveled out there was a statistically decreased risk of macular edema and vitreous hemorrhage and progression of retinopathy in the initial tight-control group.

The United Kingdom Prospective Diabetes Study (UKPDS) was a prospective, randomized trial of patients with type 2 diabetes. Intensive glucose control with insulin or oral hypoglycemic agents was compared to conventional therapy in which patients were initially treated with diet alone. In addition, intensive blood pressure control was compared to conventional management. Reduction of both glucose and blood pressure with intensive control was found to decrease the rate of progression of diabetic retinopathy.

The UKPDS demonstrated that reducing hemoglobin A1C from 7.9 to 7.0 with intensive therapy was associated with a 25% decrease in microvascular complications (as exemplified by a corresponding decrease in the need for retinal laser surgery) and that reducing blood pressure to less than 150/85 mm Hg was associated with a 34% reduction in the progression of retinopathy.
The UKPDS found that control of hypertension in type 2 diabetes is just as important as glucose control in delaying the onset or progression of diabetic retinopathy. Angiotensin-converting enzyme (ACE) inhibitors and beta blockers were equally effective in lowering blood pressure and decreasing the risk of progression of retinopathy.

To help realize the benefits demonstrated by the DCCT and the UKPDS, all physicians should familiarize themselves and their patients with diabetic ocular complications, the benefits of maintaining strict glycemic and blood pressure control, and the need for appropriate examination schedules.

Additional Systemic Controls

Diabetic nephropathy and proteinuria have been associated with more advanced retinopathy and macular edema. Optimizing the kidney status may be beneficial to the retina. ACE inhibitors such as lisinopril are known to be of benefit to the diabetic kidney. The EUCLID study (European Controlled Trial of Lisinopril in Insulin-dependent Diabetes) found that lisinopril decreases the progression of retinopathy in normotensive patients with type 1 diabetes.
Data suggest that elevated total cholesterol is directly associated with the presence or development of hard exudates, an adverse feature of macular edema. It remains to be seen if lowering serum cholesterol will decrease hard exudates and improve the visual prognosis of diabetic macular edema.

**Diabetic Retinopathy and Cardiovascular Disease**

Findings of the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) show special interrelationships between proliferative diabetic retinopathy and cardiovascular disease. The presence of PDR was observed to be an important risk indicator for the development of myocardial infarction, stroke, and amputation. These findings were noted after controlling for age and duration of diabetes. In addition, patients with PDR were at higher risk of developing diabetic nephropathy.

**PATHOGENESIS**

Elevated glucose levels may result in various metabolic abnormalities, leading to an increased production of multiple growth factors, especially vascular endothelial growth factor (VEGF). VEGF causes increased capillary permeability and abnormal vasoproliferation.
The trypsin digest—a light microscopic study of retinal blood vessels—on the right highlights an early change of diabetic retinopathy: loss of pericytes, the supportive cells of the retinal vasculature, which are more numerous in the normal digest on the left. Endothelial cells are lost later. These abnormalities are followed by the formation of microaneurysms, leaky outpouchings of the capillary walls that represent the first clinically detectable evidence of diabetic retinopathy. Other sequelae include abnormal permeability, capillary nonperfusion, and neovascularization.

**CLINICAL STAGES OF RETINOPATHY**

The effects of diabetes on the retina are manifested in progressive stages that are defined by ophthalmoscopic criteria. In the first stage, termed *nonproliferative diabetic retinopathy* (NPDR), features that reflect retinal capillary damage and breakdown in the blood-ocular barrier are noted. In the second stage, called *preproliferative diabetic retinopathy* (also referred to as *severe NPDR*), ischemic retinopathy is more prominent. In the third stage, proliferative diabetic retinopathy (PDR), progressive retinal ischemia promotes the growth of fragile new blood vessels, or neovascularization.

**DIABETIC RETINOPATHY: CLINICAL STAGES**

- Nonproliferative diabetic retinopathy (NPDR)
- Preproliferative diabetic retinopathy
- Proliferative diabetic retinopathy (PDR)
Nonproliferative Diabetic Retinopathy

Ophthalmoscopy reveals microaneurysms, hard exudates, and intraretinal hemorrhages with mild to moderate NPDR. Each of these abnormalities may occur in isolation or in combination. Patients may be asymptomatic at this stage, even as their disease is causing severe retinal damage.

Microaneurysms are usually the earliest visible manifestation of diabetic retinopathy. They appear as tiny red dots scattered in the retina posteriorly (single arrows). They may be surrounded by a ring of yellow lipid, or hard, exudates (double arrow). Exudates are the result of vascular leakage, but the specific leaking microaneurysm may not be visible ophthalmoscopically.

Intraretinal hemorrhages appear either as red dots or blots, sometimes indistinguishable from microaneurysms, or as flame-shaped hemorrhages.
Vascular leakage, fluid, and/or exudate in the macula is referred to as diabetic macular edema (DME). Compare the healthy macula on the left with the edematous macula, caused by leaking microaneurysms, on the right. When diabetic macular edema involves or threatens the fovea, it is termed clinically significant macular edema (CSME). DME is the most frequent cause of moderate visual loss that may occur at any stage of retinopathy, although it is more common and severe in the later stages. It also may be associated with normal vision and may be difficult to appreciate ophthalmoscopically.

The prevalence of diabetic macular edema is strongly associated with the duration of diabetes, according to the Wisconsin Epidemiologic Study of Diabetic Retinopathy (Klein et al, 1989b). Macular edema was present in about 5% of patients who had diabetes for 5 years or less. However, the prevalence of edema rose to about 15% among patients who had had diabetes for 15 years or more. The prevalence was slightly lower for diabetic patients not using insulin. The study also found that higher glycosylated hemoglobin levels were associated with a higher prevalence of macular edema (Klein et al, 1988).

NPDR may also be associated with cotton-wool spots, superficial white lesions with feathery edges due to infarction of the nerve fiber layer of the retina causing axoplasmic stasis.
Preproliferative Diabetic Retinopathy

In preproliferative diabetic retinopathy (PPDR), more ominous ischemic lesions occur. These include irregular dilations of retinal veins, called venous beading (shown on the slide by the arrows), intraretinal microvascular abnormalities or capillary shunt vessels (shown on the slide by the arrowheads), and extensive retinal hemorrhages. Once these signs have appeared, approximately 50% of patients will develop proliferative retinopathy within 1 year. It may be beneficial, particularly for patients with type 2 diabetes, to begin panretinal laser therapy at this stage of disease to prevent long-term visual loss.

Proliferative Diabetic Retinopathy

Proliferative diabetic retinopathy (PDR) is the major cause of blindness in diabetes. The ophthalmoscopic features include new retinal or optic disc blood vessels (neovascularization) that may be complicated by vitreous hemorrhage (the most common cause of blindness) and traction retinal detachment. Any of the nonproliferative findings, including macular edema, may also be present.

The delicate new vessels that grow on the surface of the retina resemble a tangle of hair or a fishnet. Neovascularization originating around the optic nerve head is referred to as new vessels at the disc (NVD), shown on the left. If originating elsewhere on the retina, the neovascularization is called new vessels elsewhere (NVE) shown on the right.
As these fragile new vessels grow, they may bleed into the vitreous cavity, a condition called vitreous hemorrhage.

Vitreous hemorrhage may be mild, perceived by the patient as dark spots or floaters. Alternatively, vitreous hemorrhage may be more severe and may fill the vitreous compartment with blood, decreasing the patient’s visual acuity to light perception only. Patients with these symptoms should be examined immediately by an ophthalmologist to rule out other causes of blindness such as retinal detachment and to assess for laser therapy.

Fibrosis may accompany neovascularization. Fibrous elements may contract, causing distortion, tearing, or detachment of the retina and subsequent visual loss. Severe distortion of the retinal architecture due to fibrovascular proliferation is noted in this photograph.

Neovascularization in diabetes is not always confined to the retina. Retinal ischemia may induce new vessel growth on the iris surface, shown by the arrow. Iris neovascularization, or rubeosis iridis, may lead to peripheral iris adhesions blocking the normal drainage of aqueous fluid from the eye, potentially causing acute angle-closure glaucoma.
Insulin-using diabetic patients diagnosed before age 30 have a rare risk of developing PDR within the first 5 years after diagnosis. However, after 15 years’ duration of DM, the prevalence rises to 25%, and to 55% after 20 years.

In diabetic patients diagnosed after age 30, the prevalence of PDR is 20% in insulin-using patients 20 years after diagnosis, but is less common in non-insulin users.

In summary, the clinical stages of diabetic retinopathy include nonproliferative diabetic retinopathy (NPDR), in which patients may be asymptomatic; preproliferative diabetic retinopathy (PPDR), during which laser therapy may help preserve vision; and proliferative diabetic retinopathy (PDR), a major cause of severe visual loss.
Careful and detailed ophthalmoscopic examination through dilated pupils is an important technique used to accurately grade diabetic retinopathy and to assess the need for laser photocoagulation surgery. Although most of the abnormalities are concentrated in the posterior retina, they may be difficult to appreciate with a direct ophthalmoscope, which precludes stereoscopic, wide-field viewing.

Detailed grading of retinopathy and accurate recognition of macular edema are aided by the magnified, stereoscopic view of the slit lamp biomicroscope. The wide-field view of the indirect ophthalmoscope allows visualization of the far retinal periphery, which is essential for a complete examination.

Fundus photography (left) and fluorescein angiography (right) can document areas of vascular leakage, nonperfusion, and neovascularization. Fluorescein, a yellow dye that fluoresces under cobalt-blue light, is injected intravenously. A series of photographs is taken as the dye courses through the retinal vasculature. Fluorescein angiography is useful in guiding laser surgery for macular edema. Note the leaky microaneurysms (arrows) in this patient with CSME.
Fluorescein angiography is also very sensitive in detecting fronds of neovascularization that leak profusely during the course of the angiogram. Note the dark, hypofluorescent patches (arrows) associated with the neovascular fronds, indicative of ischemia.

**TREATMENT**

The principal method used in treating diabetic retinopathy is laser photocoagulation surgery. Topical anesthesia is given; retrobulbar anesthesia may also be necessary. During the procedure, the fully alert patient sits at a device similar to a slit lamp; a contact lens is placed on the eye, allowing a magnified, stereoscopic view of the area to be treated.

Photocoagulation is usually accomplished with the argon laser, which delivers green light that is well absorbed by the retinal pigment epithelium (RPE) beneath the retina. A white laser burn of the retina and RPE is produced by the absorption of the heat energy, as demonstrated in this photograph of acute panretinal laser photocoagulation burns.
Laser Photocoagulation for Macular Edema

The photocoagulation technique used to treat CSME, known as focal macular laser, differs from that used to treat proliferative retinopathy. Focal macular laser uses a limited distribution of laser spots, delicately placed within the bed of retinal edema, and may include the direct treatment of associated leaking microaneurysms using yellow wavelength. As the edema is gradually resorbed, visual acuity may stabilize or even improve.

According to the report of the Early Treatment Diabetic Retinopathy Study (1985), sponsored by the National Eye Institute, the incidence of visual loss from CSME was reduced by focal macular laser from 16% to 7% after 2 years and from 24% to 12% after 3 years (top graph). However, the benefit of focal macular laser was substantially attenuated in patients with macular edema that was not clinically significant (bottom graph).

Optical coherence tomography (OCT), is a more novel imaging technology that uses a laser source of light to create an optical cross section of the macula similar to ultrasonography. It is a useful technique in the diagnosis and monitoring of diabetic macular edema, especially cystoid macular edema (CME). CME is often recalcitrant to laser therapy. Some degree of success in treating CME has been achieved with intravitreal steroid injection and more recently intravitreal antiVEGF injection (eg. Avstin therapy). This slide shows an example of DME and CME which resolved status post intravitreal Kenalog injection.
Laser Photocoagulation for Proliferative Retinopathy

Panretinal photocoagulation involves the widespread, peripheral administration of laser, causing extensive peripheral damage while preserving the posterior pole and macula. In a manner not completely understood, this technique causes the proliferating vessels to regress. Research indicates that the ischemic retina elaborates vasoproliferative factors, the most important of which appears to be VEGF. Photocoagulative damage of the ischemic retina eliminates the source of VEGF and other growth factors, causing vascular proliferations to regress.

Performed as an outpatient procedure, a complete panretinal photocoagulation treatment consists of about 1000 to 2000 burns or more, usually delivered in one to three sessions. A single session usually takes less than 30 minutes. Most patients are given only topical anesthesia; those who have pain may require retrobulbar anesthesia.

How effective is panretinal photocoagulation? The Diabetic Retinopathy Study, sponsored by the National Eye Institute, investigated the use of this technique. 50% or greater reduction in vision loss was noted with PRP. Those patients with high risk characteristics sustained the greatest benefit: the 2-year risk of severe visual loss, defined as visual acuity of 5/200 or worse, decreased from 26% to 11%; after 5 years there was a reduction from 50% to 26%.
Expected consequences of panretinal photocoagulation include partial loss of side vision and night vision. This loss results from the destruction of portions of the retinal periphery, where the rods are most concentrated. Occasionally, central vision may be decreased by more than one or two lines on the Snellen visual acuity chart.

Vitrectomy

For patients whose retinal complications are not amenable to photocoagulation surgery, vitrectomy (removal of the vitreous) is a treatment option to evacuate vitreous hemorrhage, repair retinal detachment, and allow treatment with panretinal photocoagulation.

Vitrectomy is a complex procedure in which the vitreous is simultaneously removed and replaced by an infusion of a modified saline solution. An intraocular fiberoptic light source allows visualization. If necessary, tractional fibrous bands are dissected and released. Intraocular laser photocoagulation, called endophotocoagulation, may also be performed at the time of surgery to expedite regression of new retinal vessels.

**PRP: SIDE EFFECTS**
- Decreased night vision
- Decreased peripheral vision

**VITRECTOMY**
- Remove vitreous hemorrhage
- Repair retinal detachment
- Allow treatment with PRP
The figure on the left shows an eye with a dense vitreous hemorrhage and light-perception vision. Vision is restored with removal of the blood by vitrectomy (figure on the right). The 1988 report of the Diabetic Retinopathy Vitrectomy Study documented a better visual outcome in patients with type 1 diabetes with PDR and vitreous hemorrhage who received early vitrectomy. Vitrectomy, however, is not a substitute for panretinal photocoagulation, which is essential in decreasing the ischemic drive.

**Treatment Options: Summary**

In summary, treatment options for diabetic eye disease include laser photocoagulation surgery for clinically significant macular edema and proliferative diabetic retinopathy, and vitrectomy for vitreous hemorrhage and retinal detachment.

Inhibitors of angiogenesis, such as anti-VEGF therapy, are being used for the treatment of some retinal vascular disorders. In the future they may be found useful as an adjuvant treatment to laser therapy in patients with diabetic macular edema or proliferative diabetic retinopathy.
Based on current knowledge of the natural history of diabetic retinopathy and the efficacy of treatment, the following screening guidelines are suggested:

1. Patients with type 1 diabetes should be evaluated annually by an ophthalmologist, beginning 5 years after diagnosis and not before age 12. Earlier evaluation is not necessary because vision-threatening retinopathy tends not to occur before puberty and is rare before 5 years’ duration of the disease.

2. Patients with type 2 diabetes should be evaluated by an ophthalmologist at the time of the initial diagnosis. These patients must be evaluated sooner than earlier-onset patients because the condition has generally been present before the time that it is first diagnosed. A small number of such patients already have macular edema or proliferative retinopathy at the time of diagnosis. After the initial screening examination, patients should be examined yearly or more frequently if the severity of the retinopathy warrants.
Hormonal and blood flow changes during pregnancy may aggravate glucose control and retinopathy. Ideally, women with diabetes who are planning a pregnancy should be examined before conception to obtain a baseline assessment of the retina and to discuss the risks of developing or exacerbating retinopathy. First trimester screening by an ophthalmologist is the typical protocol. The subsequent interval for examination will depend on the grade of baseline retinopathy. Patients with gestational diabetes do not need to be examined.

**CONCLUSION**

Improving patient’s access to and compliance with ocular examination is a priority for continued progress in the treatment of diabetic retinopathy. The WESDR showed that more than one third (36%) of patients with diabetes had missed their yearly dilated examination, and more than 60% of patients with high-risk proliferative diabetic retinopathy still had not received laser surgery 14 years later.

Timely ocular examination can decrease the risk of blindness from 50% to just 5% in those who develop proliferative diabetic retinopathy. Moreover, the financial benefits of improved access to examinations are enormous. Each 1% increase in screening of the diabetic population saves approximately $1.7 million. It has been estimated that annual savings would reach $167 million with 100% screening.

**DIABETES AND PREGNANCY**

- Ophthalmologic exam before conception
- Ophthalmologic exam during first trimester
- Follow-up depends on baseline grade

**WESDR: PATIENTS’ ACCESS AND COMPLIANCE**

- 36% missed annual ocular exam
- 60% missed laser surgery

**GOALS FOR SUCCESS**

- Timely screening reduces risk of blindness from 50% to 5%
- 100% screening estimated to save $167 million annually
Optimal systemic control of glycosylated hemoglobin, blood pressure, kidney status, and serum lipid profile is crucial in improving the systemic and ocular prognoses of diabetic patients.

The proper management of diabetic retinopathy requires a multidisciplinary approach. Ideally, the primary care physician, nutritionist, endocrinologist, nephrologist, and ophthalmologist should all work together to ensure the diabetic patient’s access to eye care, optimize systemic control, and, ultimately, help reduce the risk of blindness.

**GOALS FOR SUCCESS**

**Better systemic control of:**
- Hemoglobin $A_1C$
- BP
- Kidney status
- Serum lipids

**REDUCING THE RISK OF BLINDNESS**
- Team approach: primary care physician, ophthalmologist, nutritionist, endocrinologist, nephrologist
- Access to eye care
- Systemic control
REFERENCES


APPENDIX 1

Recommended Eye Examination Schedule for Patients with Diabetes

<table>
<thead>
<tr>
<th>Age at Onset of Diabetes Mellitus</th>
<th>Recommended Time of First Exam</th>
<th>Recommended Follow-up*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-29†</td>
<td>5 years after onset¹</td>
<td>Yearly¹</td>
</tr>
<tr>
<td>30 and older†</td>
<td>At time of diagnosis²</td>
<td>Yearly²</td>
</tr>
<tr>
<td>Prior to pregnancy</td>
<td>Prior to conception or early in the first trimester³,⁴</td>
<td>No retinopathy to nonsevere NPDR: every 3–12 months. Other stages of diabetic retinopathy: every 1–3 months.</td>
</tr>
</tbody>
</table>

* Abnormal findings may dictate more frequent follow-up examinations.
† As indicated in Wisconsin Epidemiologic Study of Diabetic Retinopathy, these are operational definitions of type 1 and type 2 diabetes based on age (age <30 years at diagnosis, type 1; age ≥30 years at diagnosis, type 2) and not pathogenetic classification.


Notes
APPENDIX 2
Resources

Selected Academy Resources

For Practitioners

Basic and Clinical Science Course, Section 12: Retina and Vitreous (updated annually).


ETDRSR Group: Photocoagulation for Diabetic Macular Edema (Videotape). 1999, 30 minutes. Reviews the findings on 4000 patients followed over a 5-year period and demonstrates photocoagulation techniques. Includes a section covering the DCCT.


For Patients and the General Public

Diabetic Retinopathy Brochure. An easy-to-understand brochure available in English and Spanish


EyeCare America Diabetes Project. Referral program for those 65 and older; for more information, patients may call 800/222-EYES.
Fluorescein Angiography (Eye Fact Sheet). A single page that explains the purpose and procedure of fluorescein angiography.

Laser Surgery of the Eye. A brochure that helps patients understand laser surgery; available in English and Spanish.

Additional Resources

Publications


Online Resources

American Academy of Ophthalmology
www.aao.org

American Diabetes Association
www.diabetes.org

Diabetic Retinopathy Studies
http://www.nei.nih.gov